File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

TitleSURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
Authors
Verstovsek, SKomatsu, NSingh, GHHJin, JLee, SEHou, HASato, TQin, AUrbanski, RShih, WZagrijtschuk, OZimmerman, CMesa, RA
Issue Date2022
Citation
Future Oncology, 2022 How to Cite?
DOI: http://dx.doi.org/10.2217/fon-2022-0596
Persistent Identifierhttp://hdl.handle.net/10722/315524
ISI Accession Number ID
WOS:000864307400003

 

DC FieldValueLanguage
dc.contributor.authorVerstovsek, S-
dc.contributor.authorKomatsu, N-
dc.contributor.authorSingh, GHH-
dc.contributor.authorJin, J-
dc.contributor.authorLee, SE-
dc.contributor.authorHou, HA-
dc.contributor.authorSato, T-
dc.contributor.authorQin, A-
dc.contributor.authorUrbanski, R-
dc.contributor.authorShih, W-
dc.contributor.authorZagrijtschuk, O-
dc.contributor.authorZimmerman, C-
dc.contributor.authorMesa, RA-
dc.date.accessioned2022-08-19T08:59:31Z-
dc.date.available2022-08-19T08:59:31Z-
dc.date.issued2022-
dc.identifier.citationFuture Oncology, 2022-
dc.identifier.urihttp://hdl.handle.net/10722/315524-
dc.languageeng-
dc.relation.ispartofFuture Oncology-
dc.titleSURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia-
dc.typeArticle-
dc.identifier.emailSingh, GHH: gillhsh@hku.hk-
dc.identifier.authoritySingh, GHH=rp01914-
dc.identifier.doi10.2217/fon-2022-0596-
dc.identifier.hkuros335356-
dc.identifier.isiWOS:000864307400003-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats